Health Condition 1: E13- Other specified diabetes mellitus
Conditions
Interventions
Intervention1: VELGRAFT: Allogenic cell-based wound dressing
Intervention2: VELGRAFT: Allogenic cell-based wound dressing, containing living human BM-MSCs and MSCs differentiated into adipocytes on a
Standard moist dressing on day 29, 36, 43, 50, 57, 64, 71, & 78)
Follow-up: At 12 weeks after the completion of treatment period
Control Intervention1: N/Ap: N/Ap
Sponsors
Datt Mediproducts Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Willing and able to provide written informed consent and to comply with the requirements of protocol 2. Subjects = 18 years of age 3. Subjects with type 1 or type 2 diabetes mellitus 4. Subjects with foot ulcer for greater than 4 weeks and less than 54 weeks at the time of screening visit 5. Subject’s foot ulcer located below malleoli and is between 1-20 cm2 (both inclusive) in size on day 1 6. Subject has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days: a. Dorsum transcutaneous oxygen test (TcPO2) with results = 30 mmHg, OR b. ABIs with results of = 0.7 and = 1.2, OR c. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg 7. Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule (Grade 1 by Wagner’s scale or Grade A-I by University of Texas Staging System), that has not shown signs of healing despite standard treatment (refer Appendix- 19.1 and 19.2) 8. Subject is able and willing to wear an off-loading device or orthopedic shoe 9. Subject whose screening laboratory values are within normal range or are considered clinically not significant by the Investigator 10. Female subjects willing to use adequate contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility) throughout the study
Exclusion criteria
Exclusion criteria: 1. Subjects with gangrene present on any part of the affected foot 2. Subjects who are hypersensitive to VELGRAFT and its contents 3. Subjects with ulcer of non-diabetic pathophysiology 4. If the subjects ulcer is over a Charcot deformity 5. Subjects with cellulitis, or other evidence of infection 6. Subject is currently being treated with chemotherapeutic agents and corticosteroids 7. Subjects with HbA1c > 10.0% 8. Subjects with positive test for HIV, HBV or HCV 9. Subject with a positive Coronavirus infection (COVID-19) on the basis of RT-PCR of respiratory specimen 10. Known hypersensitivity, contraindication or intolerance to any of the components of the investigational product 11. Subjects had a previous lower extremity amputation. 12. Subjects who have received allograft, autograft, xenograft, or cellular therapy within last 30 days of screening visit 13. Female subjects who are nursing, pregnant, or planning on becoming pregnant during the study 14. Subjects with mental or physical condition that would, in the opinion of the investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol 15. Subject is currently participating or has participated in another clinical study within the past 30 days prior to enrollment 16. Any coexisting serious or uncontrolled comorbid condition that may not make the patient eligible to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Proportion of participants with complete wound closure at 12 weeks. Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements 2. Proportion of participants reporting treatment emergent adverse events during the study periodTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of participants with complete wound closure by 24 weeks 2. Time to reach complete wound closure 3. Percentage of wound closure at 12 weeks 4. Patient reported outcome measures (36-item short form (SF-36), Quality of life in neurological disorders (Neuro QoL) and WHO-5 well-being scale)Timepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactDr Pankaj Bablani
Datt Mediproducts Private Limited
Outcome results
None listed